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High-intensity focused ultrasound (HIFU) is playing an increasingly important role in cancer therapy. Primary
synovial sarcomas of the chest wall are extremely rare. We report the first case of noninvasive HIFU therapy for the
control of synovial sarcoma. A 51-year-old man was diagnosed with spindle cell sarcoma on the left chest wall
through lumpectomy. After four cycles of chemotherapy, local recurrence of the sarcoma was detected.
Subsequent extended resection confirmed synovial sarcoma. After five cycles of a new chemotherapy option, the
sarcoma relapsed again. Then the patient received five courses of HIFU; this completely ablated the sarcoma
without complications. No chemotherapy, radiotherapy, or biological therapy has been applied since. Now the
patient is stable and has a high quality of life.
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Synovial sarcoma is a type of rare sarcoma in the soft tis-
sue near the large joints of the arm or leg. Primary syn-
ovial sarcoma of the chest wall is extremely rare. The
cytological features of the monophasic spindle cell and
biphasic subtypes of synovial sarcoma, samples of which
were obtained through fine needle aspiration, have been
reported in several case studies [1]. Surgery is the
mainstream therapy for synovial sarcoma. However, the
post-surgery recurrence rate is still as high as 60% [2].
Moreover, synovial sarcoma is not sensitive to chemother-
apy or radiotherapy [3]. So far, no report of high-intensity
focused ultrasound (HIFU) therapy for synovial sarcoma
has been found in the English literature. This report pre-
sents a case of synovial sarcoma of the left chest wall. Two
surgical procedures and postoperative chemotherapy
failed to control the tumor but HIFU therapy achieved
good clinical efficacy.
Case presentation
A solid texture mass, 2 cm in diameter, was found on the
left chest wall of a 51-year-old man accompanied with
local swelling and tenderness 1 year ago. Lumpectomy* Correspondence: dengyc001@hotmail.com
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reproduction in any medium, provided the orwas performed in a local hospital. Postoperative patho-
logical analysis confirmed the mass to be a spindle cell
sarcoma. The patient was treated with a chemotherapy
regimen of MTX 14.5 d1 +MTX 14.5 d8 +DDP 180 mg
d15 +ADM 110 mg d17. After four cycles of chemother-
apy, a similar mass with a more solid texture and some
tenderness was found in the surgical site. Therefore, the
patient was admitted to our hospital for a second surgery,
expanded resection. Postoperative immunohistochemistry
results indicated ER−, AR−, CK(Pan)±, CD34−, EMA−,
CerbB2−, S-100−, Vimentin+++, EGFR−, P63−, SMA+,
Calponin−, D2-40+, MBP−, CD99+++, β-catenin++,
confirming diagnosis of synovial sarcoma. The patient re-
ceived a new chemotherapy regimen of IFO 2 d1-5 +VP16
0.1 d1-5. However, follow-up magnetic resonance imaging
(MRI) revealed that the tumor relapsed again after five
cycles of chemotherapy. A new therapy plan was designed:
HIFU. The HIFU procedure was performed using an FEP-
BY02 HIFU system (Yuande Biomedical Engineering Co.
Ltd, Beijing, China). A vertical scanning mode was chosen
with a slice thickness of 2 mm. The ultrasonic transmitter
worked at a frequency of 1.1 MHz and 11.0 MHz. GE
LOGIQ 400CL was used for real-time monitoring during
the therapy. The ultrasonic power was 130 W. Detailed
therapeutic parameters were as follows: T1/T2 990 ms/
10 ms; 40 transmissions per therapeutic point with a dis-
tance of 2 mm between adjacent therapeutic points;This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chest MRI. (A) Before treatment, chest MRI shows enhanced tumor. (B) After treatment, arterial phase-enhanced MRI showed tumor
was completely necrotized.
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200 seconds with an interval of 2 minutes between each
unit; a spacing of 5 mm between adjacent treatment
slices. The ablation effect was measured by MRI after
the HIFU procedure.
After the first HIFU procedure, MRI demonstrated that
the treated region was indicative of coagulation necrosis
and homogeneous enhancement at the edge of the tumor.
In total, five HIFU procedures were conducted, on 15
February 2011, 26 April 2011, 30 May 2011, 28 June 2011,
and 6 September 2011. MRI conducted on 11 January
2011 and 7 September 2011 found complete coagulation
necrosis in the therapeutic area (Figure 1A and B). Biopsy
results before and after HIFU therapy are shown in
Figure 2. Residual tumor cells were not found in repeated
biopsy tests. HIFU completely ablated the tumor without
complications and no further chemotherapy, radiotherapy
or biological therapy was required for tumor control. The
patient is now stable with a high quality of life. Further col-
lection and analysis of follow-up data is underway.Figure 2 H & E staining of samples obtained by needle aspiration. (A
synovial sarcoma cells and infiltration of the muscle layer. Magnification, ×2
contained lymphocytes. Magnification, ×100.Discussion
Synovial sarcoma is characterized by local recurrence and
difficulty in treatment. Surgery is the mainstream option
for synovial sarcoma, accompanied by chemotherapy and
radiotherapy. Further studies on molecular biology have
revealed specific oncogene mutations and corresponding
protection expression could serve as therapeutic targets
[4]. Unfortunately, researchers have proved that chemo-
therapy and radiotherapy not only failed to improve
progression-free survival or overall survival rate, but also
led to poor life quality, owing to severe side effects [5].
With focused beams, HIFU can reach deep tissue and de-
liver localized warming, with temperatures reaching 70°C
within 0.5 to 5 seconds [6]. HIFU could achieve coagula-
tion necrosis through thermal effects, cavitation and
mechanical effects without affecting normal tissues out-
side the therapeutic area [7]. HIFU has been widely used
for prostate cancer [8], pancreatic cancer [9] and uterine
fibroids [10]. Further in-depth research has focused on
integration of HIFU therapy and chemotherapy or) Before HIFU treatment, the sample contained a large number of
00. (B) After treatment, tumor cells were not found, the sample only
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treat a wider range of diseases: for example, Thomas
Charrel [12] applied HIFU for the treatment of glaucoma.
However, the application of HIFU is still at an exploratory
stage. Many issues remain unsolved, such as the exact mo-
lecular biological effect of HIFU treatment, and how to
improve therapeutic and dose efficiency. Nevertheless,
HIFU represents an effective, repeatable and minimally in-
vasive therapy option.
Conclusions
This is the first report of effective noninvasive therapy
for local control of synovial sarcoma. Without doubt,
the development of HIFU will bring revolutionary tech-
nologies for cancer therapy.
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